Difference between revisions of "Samarium-153 (Quadramet)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(updated content)
m (updated also known as)
Line 13: Line 13:
  
 
==Also known as==
 
==Also known as==
Lexidronam Pentasodium, Quadramet, Samarium [153 SM], Samarium Sm 153 Lexidronam Injection, samarium Sm 152 oxide, <sup>152</sup>Sm<sub>2</sub>O<sub>3</sub>.
+
153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), Lexidronam Pentasodium, Quadramet, Samarium [153 SM], Samarium Sm 153 Lexidronam Injection, samarium Sm 152 oxide, <sup>152</sup>Sm<sub>2</sub>O<sub>3</sub>.
  
 
==References==
 
==References==

Revision as of 06:21, 17 May 2013

General information

Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

Also known as

153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), Lexidronam Pentasodium, Quadramet, Samarium [153 SM], Samarium Sm 153 Lexidronam Injection, samarium Sm 152 oxide, 152Sm2O3.

References